Comparative Pharmacology
Head-to-head clinical analysis: ALLERFED versus SUDAFED 24 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALLERFED versus SUDAFED 24 HOUR.
ALLERFED vs SUDAFED 24 HOUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALLERFED is a combination of an antihistamine (fexofenadine) and a decongestant (pseudoephedrine). Fexofenadine is a selective peripheral H1-receptor antagonist that blocks histamine effects, reducing allergy symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor activation, causing vasoconstriction of nasal mucosa.
Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
1 tablet (pseudoephedrine 60 mg / triprolidine 2.5 mg) orally every 4-6 hours; not to exceed 4 doses per 24 hours.
120 mg orally every 24 hours (extended-release tablet).
None Documented
None Documented
Terminal elimination half-life 20-24 hours; clinically significant for once-daily dosing in seasonal allergic rhinitis.
Terminal elimination half-life 9-16 hours (mean 11 hours) in adults; prolonged in renal impairment (up to 24-30 hours in severe insufficiency); clinically relevant for dosing interval (every 24 hours)
Primarily renal (approximately 60-70% as unchanged drug and metabolites); minor biliary (10-15%); fecal (5-10%).
Renal 70-90% unchanged; minor hepatic metabolism to inactive metabolites; biliary/fecal excretion negligible (<5%)
Category C
Category C
Decongestant
Decongestant